Ahmed Babiker1,2,3, Lloyd G Clarke4, Melissa Saul1, Julie A Gealey1, Cornelius J Clancy1,5,6, M Hong Nguyen1,4,5, Ryan K Shields1,4,5. 1. Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. 2. Division of Infectious Diseases Emory University School of Medicine, Atlanta. 3. Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. 4. Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 5. XDR Pathogens Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 6. Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA.
Abstract
BACKGROUND: Carbapenem-resistant gram-negative bacteria (CRGNB) continue to present a global healthcare crisis. We aimed to identify emerging trends of CRGNB over nearly 2 decades and describe the impact of CRGNB on patient outcomes. METHODS: Patients from whom CRGNB were isolated between 2000 and 2017 were included in the study. Carbapenem resistance was defined by the most recent breakpoints and applied across the study period. Patient demographics, clinical characteristics, and outcomes were retrieved from the electronic health record. RESULTS: A total of 94 888 isolates from 64 422 patients were identified; 9882 (10%) isolates from 4038 patients were carbapenem-resistant. Pseudomonas aeruginosa was the most common CRGNB each year. The second most common CRGNB emerged in waves over time. Carbapenem daily defined doses increased in parallel with CRGNB rates (R2 = 0.8131). The overall 30-day mortality rate was 19%, which decreased from 24% in 2000 to 17% in 2017 (P = .003; R2 = .4330). Among patients with CRGNB bloodstream infections (n = 319), overall 30- and 90-day mortality rates were 27% and 38%, respectively. Charlson score (adjusted odds ratio [aOR], 1.11 per point), intensive care unit residence (aOR, 7.32), and severe liver disease (aOR, 4.8.4) were independent predictors of 30-day mortality, while receipt of transplantation was associated with lower rates of death (aOR, 0.39). Among patients admitted between 2011 and 2017 (n = 2230), 17% died during hospitalization, 32% were transferred to long-term care facilities, and 38% were discharged home. CONCLUSIONS: CRGNB emerged in waves over time, causing high rates of mortality. Despite increasing rates of CRGNB, overall patient outcomes have improved, suggesting that recognition and novel therapeutics have made a major impact.
BACKGROUND: Carbapenem-resistant gram-negative bacteria (CRGNB) continue to present a global healthcare crisis. We aimed to identify emerging trends of CRGNB over nearly 2 decades and describe the impact of CRGNB on patient outcomes. METHODS: Patients from whom CRGNB were isolated between 2000 and 2017 were included in the study. Carbapenem resistance was defined by the most recent breakpoints and applied across the study period. Patient demographics, clinical characteristics, and outcomes were retrieved from the electronic health record. RESULTS: A total of 94 888 isolates from 64 422 patients were identified; 9882 (10%) isolates from 4038 patients were carbapenem-resistant. Pseudomonas aeruginosa was the most common CRGNB each year. The second most common CRGNB emerged in waves over time. Carbapenem daily defined doses increased in parallel with CRGNB rates (R2 = 0.8131). The overall 30-day mortality rate was 19%, which decreased from 24% in 2000 to 17% in 2017 (P = .003; R2 = .4330). Among patients with CRGNB bloodstream infections (n = 319), overall 30- and 90-day mortality rates were 27% and 38%, respectively. Charlson score (adjusted odds ratio [aOR], 1.11 per point), intensive care unit residence (aOR, 7.32), and severe liver disease (aOR, 4.8.4) were independent predictors of 30-day mortality, while receipt of transplantation was associated with lower rates of death (aOR, 0.39). Among patients admitted between 2011 and 2017 (n = 2230), 17% died during hospitalization, 32% were transferred to long-term care facilities, and 38% were discharged home. CONCLUSIONS: CRGNB emerged in waves over time, causing high rates of mortality. Despite increasing rates of CRGNB, overall patient outcomes have improved, suggesting that recognition and novel therapeutics have made a major impact.
Authors: S M Bartsch; J A McKinnell; L E Mueller; L G Miller; S K Gohil; S S Huang; B Y Lee Journal: Clin Microbiol Infect Date: 2016-09-15 Impact factor: 8.067
Authors: Ryan K Shields; M Hong Nguyen; Brian A Potoski; Ellen G Press; Liang Chen; Barry N Kreiswirth; Lloyd G Clarke; Gregory A Eschenauer; Cornelius J Clancy Journal: Antimicrob Agents Chemother Date: 2014-12-22 Impact factor: 5.191
Authors: Ryan K Shields; M Hong Nguyen; Liang Chen; Ellen G Press; Brian A Potoski; Rachel V Marini; Yohei Doi; Barry N Kreiswirth; Cornelius J Clancy Journal: Antimicrob Agents Chemother Date: 2017-07-25 Impact factor: 5.191
Authors: Mario Venditti; Marco Falcone; Alessandra Micozzi; Paolo Carfagna; Fabrizio Taglietti; Pietro F Serra; Pietro Martino Journal: Haematologica Date: 2003-08 Impact factor: 9.941
Authors: David van Duin; Cesar A Arias; Lauren Komarow; Liang Chen; Blake M Hanson; Gregory Weston; Eric Cober; Omai B Garner; Jesse T Jacob; Michael J Satlin; Bettina C Fries; Julia Garcia-Diaz; Yohei Doi; Sorabh Dhar; Keith S Kaye; Michelle Earley; Andrea M Hujer; Kristine M Hujer; T Nicholas Domitrovic; William C Shropshire; An Dinh; Claudia Manca; Courtney L Luterbach; Minggui Wang; David L Paterson; Ritu Banerjee; Robin Patel; Scott Evans; Carol Hill; Rebekka Arias; Henry F Chambers; Vance G Fowler; Barry N Kreiswirth; Robert A Bonomo Journal: Lancet Infect Dis Date: 2020-03-06 Impact factor: 25.071
Authors: Louise M Oleksiuk; M Hong Nguyen; Ellen G Press; Cassaundra L Updike; Jessica A O'Hara; Yohei Doi; Cornelius J Clancy; Ryan K Shields Journal: Antimicrob Agents Chemother Date: 2013-11-18 Impact factor: 5.191
Authors: John P Donnelly; Jayme E Locke; Paul A MacLennan; Gerald McGwin; Roslyn B Mannon; Monika M Safford; John W Baddley; Paul Muntner; Henry E Wang Journal: Clin Infect Dis Date: 2016-05-23 Impact factor: 9.079
Authors: Ahmed Babiker; Daniel R Evans; Marissa P Griffith; Christi L McElheny; Mohamed Hassan; Lloyd G Clarke; Roberta T Mettus; Lee H Harrison; Yohei Doi; Ryan K Shields; Daria Van Tyne Journal: J Clin Microbiol Date: 2020-08-24 Impact factor: 5.948
Authors: Eilish McCann; Arjun Srinivasan; C Andrew DeRyke; Gang Ye; Daryl D DePestel; John Murray; Vikas Gupta Journal: Open Forum Infect Dis Date: 2018-09-21 Impact factor: 3.835
Authors: Amanda Vivo; Margaret A Fitzpatrick; Katie J Suda; Makoto M Jones; Eli N Perencevich; Michael A Rubin; Swetha Ramanathan; Geneva M Wilson; Martin E Evans; Charlesnika T Evans Journal: BMC Infect Dis Date: 2022-05-24 Impact factor: 3.667
Authors: Jessica R Howard-Anderson; Michelle Earley; Lauren Komarow; Lilian Abbo; Deverick J Anderson; Jason C Gallagher; Matthew Grant; Angela Kim; Robert A Bonomo; David van Duin; L Silvia Muñoz-Price; Jesse T Jacob Journal: Infect Control Hosp Epidemiol Date: 2022-02-02 Impact factor: 6.520
Authors: David S Khoury; Adam K Wheatley; Mitchell D Ramuta; Arnold Reynaldi; Deborah Cromer; Kanta Subbarao; David H O'Connor; Stephen J Kent; Miles P Davenport Journal: Nat Rev Immunol Date: 2020-11-02 Impact factor: 53.106